Ad-SGE-DKK3 gene therapy - Kyorin

Drug Profile

Ad-SGE-DKK3 gene therapy - Kyorin

Alternative Names: Ad-SGE-DKK-3 gene therapy - Kyorin; Ad-SGE-DKK3/REIC gene therapy - Kyorin; Ad-SGE-REIC gene therapy - Kyorin; Ad-SGE-REIC/Dkk-3 gene therapy - Kyorin; Ad-SGE-REIC/DKK3 gene therapy - Kyorin; Adenovirus super gene expression DKK3 gene therapy - Kyorin; Dickkopf3/reduced expression in immortalised cells gene therapy - Kyorin; Dkk-3 gene therapy - Kyorin; Dkk-3/REIC gene therapy - Kyorin; DKK3 gene therapy - Kyorin; DKK3/REIC gene therapy - Kyorin; Malignant pleural mesothelioma gene therapy - Kyorin; Reduced expression in immortalised cells/Dickkopf-3 gene therapy - Kyorin; REIC gene therapy - Kyorin; REIC/DKK3 gene therapy - Kyorin

Latest Information Update: 10 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Momotaro-Gene; Okayama University
  • Class Gene therapies
  • Mechanism of Action Apoptosis stimulants; DKK3 expression modulators; Gene transference; Immunostimulants; Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma

Most Recent Events

  • 29 Jul 2016 Ad-SGE-DKK3 gene therapy is still in phase I/II trials for Mesothelioma (malignant pleural) in Japan (Kyorin Holdings Investor Information, July 2016)
  • 01 May 2014 Phase-I/II clinical trials in Mesothelioma in Japan (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top